scholarly journals Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury

2015 ◽  
Vol 105 (5) ◽  
pp. 393 ◽  
Author(s):  
S Naidoo ◽  
D Evans ◽  
E Jong ◽  
K Mellet ◽  
R Berhanu
Keyword(s):  
Liver Injury ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals CYP2E1, GSTM1, and GSTT1 genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients

Heliyon ◽  
2021 ◽  
Vol 7 (4) ◽  
pp. e06852
Author(s):  
Noppadol Chanhom ◽  
Sukanya Wattanapokayakit ◽  
Nusara Satproedprai ◽  
Supharat Suvichapanich ◽  
Surakameth Mahasirimongkol ◽  
...  
Keyword(s):  
Liver Injury ◽  
Genetic Polymorphisms ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Tuberculosis Patients ◽  
Drug Induced Liver Injury

scholarly journals Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens

2020 ◽  
Author(s):  
Paola Nicoletti ◽  
Harshad Devarbhavi ◽  
Ashish Goel ◽  
Radha Venkatesan ◽  
Chundamannil E. Eapen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Injury ◽  
Genetic Risk ◽  
Genetic Risk Factors ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Drug Regimens

scholarly journals Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Lina Tao ◽  
Xiaoyu Qu ◽  
Yue Zhang ◽  
Yanqing Song ◽  
Si-xi Zhang
Keyword(s):  
Liver Injury ◽  
Liver Function ◽  
Randomized Controlled Trials ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Prophylactic Therapy ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Randomized Controlled

Background. Prophylactic therapy with silymarin to prevent the development of antituberculosis drug-induced liver injury (anti-TB DILI) has been under debate. We aimed to evaluate the effect of silymarin in the prevention of anti-TB DILI. Methods. We searched MEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to 30th November 2018. Randomized controlled trials (RCTs) that compared silymarin and placebo to prevent anti-TB DILI were included. All statistical analyses were conducted using STATA 12.0 software. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CIs) were used to evaluate the effect of silymarin. The quality of included studies was assessed according to Cochrane handbook. Funnel plots and Egger’s tests were carried out to evaluate publication bias. Sensitivity analysis was conducted to assess the influence of each study. Results. A total of 1198 patients from five RCTs (585 with silymarin and 613 with placebo groups) were included. Overall, silymarin significantly reduced the occurrence of anti-TB DILI at week 4 [RR: 0.33, 95% CI (0.15, 0.75)]. In addition, silymarin exerted protective effect on liver function in patients undergoing anti-TB drugs [SMD = − 0.15, 95% CI (−0.24, −0.07), P < 0.001 (ALT); SMD =−0.14, 95% CI (−0.23, −0.06), P = 0.001(AST); SMD =−0.12, 95% CI (−0.20, −0.03), P = 0.008 (ALP)]. Silymarin led to similar AEs in placebo groups [OR: 1.09, 95% CI (0.86, 1.39), P = 0.47]. Conclusion. Prophylactic therapy of silymarin is contributed to a noticeably reduced risk of development of anti-TB DILI four weeks after the initiation. In addition, silymarin significantly improved the liver function in patients who are receiving anti-TB drugs.

Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis

2010 ◽  
Vol 61 (4) ◽  
pp. 323-329 ◽  
Author(s):  
Wan Beom Park ◽  
Won Kim ◽  
Kook Lae Lee ◽  
Jae-Joon Yim ◽  
Moonsuk Kim ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Injury ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury

The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study

2014 ◽  
Vol 40 (1) ◽  
pp. 110-115 ◽  
Author(s):  
R. Chen ◽  
Y. Zhang ◽  
S. Tang ◽  
X. Lv ◽  
S. Wu ◽  
...  
Keyword(s):  
Liver Injury ◽  
Case Control Study ◽  
Case Control ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Control Study

scholarly journals Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury

2021 ◽  
Vol Volume 14 ◽  
pp. 3667-3671
Author(s):  
Yi-Hui Liu ◽  
Yan Guo ◽  
Hong Xu ◽  
Hui Feng ◽  
Dong-Ya Chen
Keyword(s):  
Liver Disease ◽  
Liver Injury ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals The Variant at TGFBRAP1 but Not TGFBR2 Is Associated with Antituberculosis Drug-Induced Liver Injury

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Jingwei Zhang ◽  
Zhenzhen Zhao ◽  
Hao Bai ◽  
Lin Jiao ◽  
Qian Wu ◽  
...  
Keyword(s):  
Liver Injury ◽  
Genetic Model ◽  
Joint Effect ◽  
Dependent Manner ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Effect Analysis ◽  
Tuberculosis Patients ◽  
Drug Induced Liver Injury ◽  
Increased Risk

Background. TGFBRAP1 and TGFBR2 play important roles in the TGF-β/smad signalling pathway and may disturb liver homeostasis by regulating liver injury and renewal. However, little is known about the association between their genetic polymorphisms and antituberculosis drug-induced liver injury (ATDILI), so we explored the association between their variants and the susceptibility to ATDILI. Materials and Methods. A total of 746 tuberculosis patients were prospectively enrolled, and fifteen selected SNPs were genotyped. The allele, genotype, and genetic model frequencies of the variants were compared between patients with or without ATDILI, as well as the joint effect analysis of SNP-SNP interactions. The odds ratio (OR) with the corresponding 95% confidence interval (CI) was calculated. Results. The A variant at rs17687727 was significantly associated with an increased risk for ATDILI (OR 1.55; 95% CI: 1.08–2.22; p=0.016), which is consistent with the results in the additive and dominant models. Other allele, genotype, and genetic model frequencies were similar in the two groups for the other fourteen SNPs (all p>0.05). Conclusion. Our study first implied that the A variant of rs17687727 in TGFBRAP1 influenced the susceptibility to ATDILI in first-line antituberculosis combination treatment in the Han Chinese population in a dependent manner.

Genome‐Wide Analysis of DNA Methylation and Antituberculosis Drug‐Induced Liver Injury in the Han Chinese Population

2019 ◽  
Vol 106 (6) ◽  
pp. 1389-1397 ◽  
Author(s):  
Cong Huai ◽  
Yuqi Wei ◽  
Mo Li ◽  
Xiaoqing Zhang ◽  
Hao Wu ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Liver Injury ◽  
Chinese Population ◽  
Han Chinese ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Han Chinese Population ◽  
Drug Induced Liver Injury ◽  
Genome Wide Analysis ◽  
Genome Wide
Sign in / Sign up

Export Citation Format

Share Document